QOL Medical: Free Testing as a Sales-Lead System

In the QOL Medical Sucraid settlement, QOL and its co-owner and CEO agreed to pay $47 million to resolve allegations of pharmaceutical kickbacks through free Carbon 13 breath testing. The manufacturer paid a laboratory to analyze the tests, sent the results to its sales force and tracked whether positive results became Sucraid prescriptions. A patient got a free test. QOL got a reason for its next sales call.

The Justice Department announced the settlement on November 15, 2024. Of the total $47 million, approximately $43.6 million was the federal portion and approximately $3.4 million was a recovery for state Medicaid programs. Four former employees brought the False Claims Act qui tam case, and the government joined part of it. QOL and its CEO admitted and accepted responsibility for the testing and marketing facts set out in the signed settlement agreement.

What QOL Admitted About Free Carbon 13 Tests

QOL’s free Carbon 13 tests supplied a commercial program for Sucraid, the company’s principal rare-disease drug. Beginning in 2018, QOL distributed breath-test kits to health care providers and asked them to give the kits to patients with common gastrointestinal symptoms. QOL claimed the test could “rule in or rule out” congenital sucrase-isomaltase deficiency, the rare genetic disorder known as CSID.

Sucraid treats that genetic condition. People with CSID have reduced activity of an enzyme needed to digest sucrose and sugars from other starches, causing symptoms that can include diarrhea, abdominal pain, bloating and gas. QOL marketed the possibility that adults with symptoms of irritable bowel syndrome had undiagnosed CSID.

The agreement makes the test’s limits plain. The Carbon 13 breath test assesses sucrase activity. Low activity can occur in CSID and in other conditions, and the test does not specifically diagnose CSID. The agreement also states that the test was not FDA-approved. The commercial pitch turned a result about enzyme activity into a reason to prescribe a drug for a particular genetic condition.

The free diagnostic testing program covered both the kit and the laboratory analysis. QOL paid the laboratory approximately $105 for each test and the weekly results sent back to the company. Before its arrangement with QOL, the laboratory had charged the public approximately $140 for testing. QOL also knew the laboratory marketed the test for conditions other than CSID and paid it to stop that marketing.

That last payment matters. QOL knew the test had uses beyond the disease its drug treated, while its sales message presented the test as a way to identify that disease.

Test Results Became a Prescriber List

The laboratory gave individual results to the ordering provider and aggregate weekly results to QOL. QOL’s copy omitted patient names but retained the provider’s name and each patient’s age, gender, symptoms and test result. The commercial team used those fields to identify potential Sucraid patients and follow up with their providers.

A patient name was unnecessary for that sales call. The company knew which provider had ordered a test and which result gave its representative a reason to call. Removing a patient’s name left the commercial value of the report intact.

QOL paid for more than 75,000 tests between 2018 and 2022. Approximately 30% were positive for low sucrase activity. The company instructed representatives to call providers whose patients had positive results, then tracked whether representatives converted those results into prescriptions. The business measured the path from a laboratory result to a sale.

The whistleblowers’ amended complaint supplies the operational detail behind the kits. It describes QOL’s subsidiary, One Patient Services, assembling and distributing them to doctors, patients and sales representatives. The complaint identifies the laboratory as Metabolic Solutions. Patients took the tests home and mailed their breath samples to the laboratory, which sent reports directly to their doctors. A program presented in the examining room thus depended on kit distribution, laboratory processing and commercial follow-up inside different businesses.

The CEO Reviewed the Pitch and Kept the Results Flowing

QOL’s CEO approved the free testing arrangement, the use of results for marketing and the program’s continuation. He attended a national sales training in 2019 and reviewed slides suggesting that representatives tell providers:

The same agreement says some representatives made claims about the test’s ability to definitively diagnose CSID that published scientific literature did not support. The training message supplied certainty the test could not.

In January 2019, after reviewing guidance from the Department of Health and Human Services’ Office of Inspector General, the CEO emailed other executives about providing the test without making it central to marketing, dropping the word “free” and likely stopping the sharing of results with sales representatives. QOL stopped using “free” in the marketing materials, then resumed. It continued sending results to sales until September 2022.

The wording changed before the underlying practice did. For an insider, the email and the continued distribution of reports show different decisions: what management recognized, what it changed and what it kept running.

The complaint also quoted an earlier CEO email comparing the commercial value of adult and pediatric prescribers:

In the email quoted by the whistleblowers, the CEO described the value of the physician relationships as nearly the same despite the shorter duration of adult prescriptions. The complaint alleged that each prescription was worth $8,000 a month in revenue, making even short-lived prescriptions profitable. New patients could make up for patients who stopped taking the drug.

The CEO joined the company’s civil resolution personally.

What the Whistleblowers Said Happened Inside Sales

The former employees alleged that QOL pushed representatives to sell the test’s reliability while avoiding questions about it. Their complaint described the instruction directly:

The complaint alleged that representatives touted test accuracy beyond what internal company documents supported. It also alleged that the convenience of the free test steered patients away from genetic testing or biopsies that could establish a different diagnosis.

The alleged targeting began before a patient received a kit. According to the complaint, QOL used drug distribution data to identify providers prescribing medicines for irritable bowel syndrome and find more recipients for its free tests. The manufacturer could target a prescriber through existing prescribing habits, then return with a sales call prompted by a new test result.

The employees also described a separate honorarium arrangement paying doctors $400 for no more than an hour listening to a sales pitch and giving feedback on promotional material. They alleged the supposed draft had already been mass-produced. The presentation ended by asking how motivated the doctor was to test patients for CSID and treat positive results with Sucraid. The complaint portrayed the payment as a way to buy prescribing interest under the cover of asking for advice.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks can work through a free service that steers a patient toward a government-paid drug. In QOL’s case, the government alleged that payments to the laboratory bought results that directed sales staff to prescribers, while covering patients’ testing costs encouraged Sucraid purchases. The alleged false claims were for Sucraid reimbursed by Medicare, Medicaid, TRICARE and the Department of Veterans Affairs.

A manufacturer can influence the prescribing decision upstream of the claim for the dispensed drug. Here, the government’s allegation connected the manufacturer’s laboratory spending to those later drug claims.

The 2017 Journal of AHIMA review Busting Bad Medicine: A Call to Action Addressing Healthcare, Fraud, Waste, and Abuse describes diagnostic-laboratory arrangements in which referral payments fed government bills for unnecessary tests. QOL’s arrangement put the commercial return further along the patient’s treatment: the manufacturer paid for testing and tracked the drug prescriptions that followed.

A close parallel is Ultragenyx’s $6 million settlement announced in December 2023. The government alleged that Ultragenyx paid for genetic tests and separately paid for test-result information used to induce Crysvita prescriptions and referrals. In both cases, the manufacturer obtained something commercially useful from the diagnostic process: information it could use to pursue prescriptions.

Sales Controls After the Settlement

QOL and its CEO entered a five-year corporate integrity agreement with the inspector general, effective November 1, 2024. Its requirements reach the commercial functions that made the testing program work.

The agreement requires policies for sales call plans, promotional and disease-state materials, payments for services from healthcare professionals, and compensation for employees performing promotional work. It requires employee training, board oversight, independent reviews of systems and transactions, and annual reports to the inspector general.

What Evidence Is Needed to Prove Fraud?

For a case like QOL’s, the evidence connects the free testing, the laboratory’s data, the sales instructions and the resulting government-paid prescriptions. The agreement’s admissions show why a result report, training slide or management email can matter alongside a payment record.

A laboratory agreement and invoices can explain what the manufacturer paid to receive. The reports show which provider and patient fields reached the commercial team. Sales call plans and follow-up records show how those results became contact with a prescriber. Conversion reports connect the test program to the prescription objective, while claims records identify the government payment at the end.

The CEO’s email adds another part of the story: management’s response after reviewing guidance. Comparing that response with the reports that continued to circulate can show whether a promised change reached the sales operation. The people handling laboratory accounts, commercial data, field sales or training may see different parts of the same sequence in their ordinary work.

We work with pharmaceutical whistleblowers to connect those parts. Your knowledge of why a report was produced, who received it and what they were told to do with it can explain a transaction that looks routine on an invoice.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the QOL case, the agreement provided approximately $8 million for the whistleblowers collectively from the federal settlement proceeds.

You Saw Where the Test Results Went

If you handled testing contracts, result reports or sales training tied to a drug, tell our whistleblower experts how the program worked. We build your strongest case around the connection between testing, prescribing and government payments, bring in pharmaceutical kickback whistleblower lawyers, and stay alongside you throughout.